🎥In my new job as head of dept I’m launching a youtube video channel 🏆 Europe’s first SP RPLND – Video Prize winner at @ERUSrobotics IMHO SP offers a more favorable instrument angle fully hidden ports below the underwear line ▶️ youtu.be/ShwGvynqsg8?is=srD4…

This is one of the best pieces I’ve read in a long time. Many thanks to @anish_koka for this superb piece and thoughtful recounting. Those who really know @VPrasadMDMPH know he will do even more good and rise even higher.

RT @anish_koka: x.com/i/article/203031182839…

Our @JCO_ASCO commentary is out today: “BCG and Beyond: Is Systemic Immunotherapy for BCG-Naïve NMIBC Progress or Overreach?” Systemic IO has now entered the BCG-naïve high-risk NMIBC space. The signal is real. The interpretation must be disciplined. Thread below. 🧵 #BladderCancer #GU26 #EAU26 @AndreaNecchi @BrigidaMaiorano @shilpaonc @UrogerliMD @pjhensley11 @spsutkaMD @AmirHorowitz @IBCG_BladderCA @JCO_ASCO #OncSurgery

in J Urol this month a decision analysis of PLND during RP Take home message: benefits of PLND outweigh risk for most patients. auajournals.org/doi/10.1097/… @VickersBiostats @UrologyMSK #prostatecancer @Uroweb @AmerUrological

It's out 🚀 Our multicentric collaboration just got published in @BJUIjournal. Huge thanks to all our incredible co-authors and the @YAUpenile_tesCa who made this work possible. Read it here: bjui-journals.onlinelibrary.… @MaartenAlbersen, @Brouwer_MD_PhD, @BE_Ayres, @CDFankhauser

New out in @TheLancetOncol with Ted Schaeffer: pubmed.ncbi.nlm.nih.gov/4103… "Revisiting prostate cancer active surveillance candidacy" A close look at the fallacy and risks of active surveillance (AS) in unselected intermediate risk (IR) men. @wandering_gu @TylerSbrt

Ever wondered whether elective scrotal surgery really needs perioperative antibiotic prophylaxis (PAP)? 🤔 Our new @wjurol study found a 3× lower SSI rate (12% vs 4%; p=0.058) and fewer readmissions (26% vs 16%; p=0.13) with PAP. Although not statistically significant, PAP may still help protect selected high-risk patients from postoperative infections. In an era of rising antimicrobial resistance, routine prophylaxis warrants careful reconsideration! 💊 🔗 Full text – rdcu.be/eIo6F @MaximeValle5 @StanglFabian @endouro @AgostinoMattei @CDFankhauser

Would surgery add survival benefit to the systemic treatment in patients with oligometastatic prostate cancer ? A new data highlights this; 👉Adding radical prostatectomy to best systemic therapy cut 5-yr cancer-specific mortality from 23% to 13% (HR 0.39, p=0.045). Early termination of study, OS benefit not statistically significant; 14% had major surgery complications. 👉Supports further efforts for local therapy systemic treatment in oligomet prostate cancer. doi.org/10.1016/j.eururo.202… @EUplatinum @OncoAlert @ONCOassist @APCCC_Lugano

Still leading the pack! @EUplatinum

@JoshMeeks provides an amazing overview of the significant data emerging in the BCG-unresponsive NMIBC space, focusing on the CIS cohorts. We also discuss the recent ODAC decision on UGN-102 for lower risk disease which was recently FDA approved. spotifycreators-web.app.link…

It's #BladderCancerAwarenessMonth! Urologists play a key role in smoking cessation counseling. Tune in as @CDFankhauser and Dr. Richard Matulewicz @MSKCancerCenter discuss #URO54 open.spotify.com/episode/1LU…

Thanks @Cacciamani_MD 🙏

New results from the CREST Study (NCT04165317) for HR-NMIBC: Adding sasanlimab to BCG induction maintenance shows: •32% ⬇️of EFS event (HR 0.68, p=0.0095) •>50% reduction in HG recurrence •No difference in overall survival (OS interim HR 1.13, p=0.6791) #AUA25 #bladdercancer

More great data from Alberta: @urethrologist present long-term urinary toxicity following various tx combinations for #prostatecancer RP seems to do the best, but none of these curves flattens over time. #aua25

Nobel laureate Bill Kaelin on Killing the Science Golden Goose. "This is especially worrisome because becoming a scientist is largely taught by apprenticeship, with each generation teaching the next. We risk losing the next generation, our “seed corn”" amjmed.com/article/S0002-934…

Great topic and speaker

Tired of the noise on @X? Join our @telegram channel w/all the key European Urology Network updates and important #urology pubs in one place. No Elon musk tweets or ads just pubs and your own community. Subscribe info below 👇 @Uroweb @AmerUrological #AcademicResearch

Rethinking Post-Chemo Surgery in NSGCT: 🔘Mass size alone isn’t enough to decide on RPLND after chemotherapy. 🔘Teratoma or yolk sac tumor in orchiectomy significantly raises the risk of residual disease. @Annals_Oncology @tompowles1 @myESMO @Uroweb @OncoAlert annalsofoncology.org/article…

💫🌟New Review on Testicular Germ Cell Tumors! 🌟💫 @nirmishsingla @AdityaBagrodia  Dr #EzraBaraban @yalepathology @CDFankhauser @yasserged @JAMA_current @OncoAlert 💡 Key Insights: 🧬 Epidemiology & Risk Factors 🔹 Most common solid malignancy in men aged 15-40 🔹 ~10,000 cases annually in the U.S. 🔹 Risk factors: Cryptorchidism, family history, infertility, cannabis use, Klinefelter syndrome 🩺 Clinical Presentation & Diagnosis 🔹 Painless testicular mass is the most common symptom 🔹 Diagnosis: Scrotal ultrasound tumor markers (AFP, β-hCG, LDH) 📊 Staging & Treatment 🔹 Stage I (70-75%): Orchiectomy surveillance or adjuvant therapy 🏥 🔹 Stage II (20%): Lymph node involvement, treated with chemo, RPLND, or RT 🔹 Stage III (10%): Distant metastases → BEP/EP/VIP chemotherapy 💉 🎯 Survival & Long-term Effects 🔹 5-year survival rates: 99% (Stage I), 92% (Stage II), 85% (Stage III) 🔹 Long-term effects: Cardiovascular disease, secondary malignancies, infertility, hypogonadism, psychosocial impact 🧪 Emerging Biomarkers & Future Directions 🔹 miR-371a-3p: High sensitivity (91%) & specificity (94%) for early detection 🔹 Research is ongoing to refine risk stratification & de-escalate treatment @UCSD_Urology @UCSDCancer @UCSDHealth @DrRanaMcKay @MadamSurgeonMD @cjkane10 @endourologyucsd @JohnsHopkinsUni1 #OncoUrology #TesticularCancer #UroOncology #OncoTwitter #CancerResearch #MedicalOncology jamanetwork.com/journals/jam…